Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Avapritinib (BLU-285) is a dual inhibitor of the mutant KIT receptor (KIT D816V, IC50: 0.27 nM) and PDGFRα (PDGFRα D842V, IC50: 0.24 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 80.00 | |
5 mg | In stock | $ 197.00 | |
10 mg | In stock | $ 322.00 | |
25 mg | In stock | $ 547.00 | |
50 mg | In stock | $ 788.00 | |
100 mg | In stock | $ 1,080.00 | |
500 mg | In stock | $ 2,180.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 216.00 |
Description | Avapritinib (BLU-285) is a dual inhibitor of the mutant KIT receptor (KIT D816V, IC50: 0.27 nM) and PDGFRα (PDGFRα D842V, IC50: 0.24 nM). |
Targets&IC50 | c-Kit (D816V):0.27 nM, PDGFRα (D842V):0.24 nM |
In vitro | Cellular activity of Avapritinib on KIT D816 mutants is measured by autophosphorylation in the human mast cell leukemia cell line HMC1.2, and the P815 mouse mastocytoma cell line with IC50=4 and 22 nM, respectively. In Kasumi-1 cells, at positive AML cell line with a KIT exon 17 N822K mutation, Avapritinib potently inhibits KIT N822K mutant autophosphorylation (IC50: 40 nM), downstream signaling, as well as cellular proliferation (IC50: 75 nM)[1]. |
In vivo | BLU-285 (0.3-30 mg/kg) reduces tumor volume in a P815 KITD814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner. Formulations containing BLU-285 have been used to treat KIT- and PDGFRα-driven malignancies. |
Animal Research | A Kasumi-1 luc+ AML NOG SCID mouse femoral injection model is used to assess the efficacy of Avapritinib (BLU-285) in KIT exon 17-mutated CBF-AML. Following a 21 day post-injection latency period, mice are dosed with Avapritinib orally, once daily at 10 mg/kg or 30 mg/kg through day 45. Control groups are treated with vehicle or Cytarabine administered 100 mg/kg i.p once weekly. |
Synonyms | BLU-285 |
Molecular Weight | 498.56 |
Formula | C26H27FN10 |
CAS No. | 1703793-34-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
Ethanol: 3 mg/mL
DMSO: 50 mg/mL (100.29 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Avapritinib 1703793-34-3 Angiogenesis Tyrosine Kinase/Adaptors PDGFR c-Kit CD117 Platelet-derived growth factor receptor BLU-285 BLU285 SCFR Inhibitor BLU 285 inhibit inhibitor